The subgroup of SSNS without SDNS/FRNS should be renamed from "SSNS" to "SSNS without FR"
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GENERAL COMMENTS
Dr Chan et al submitted a paper on a protocol of study about the primary nephrotic syndrome in children. The paper is easy to read but I have some major comments 1-Title: Primary nephrotic syndrome means idiopathic nephrotic syndrome and membranous nephropathy while authors are clearly oriented to study the idiopathic nephrotic syndrome 2-intro: P6L7: constellation of clinical signs: there is only one clinicla sign and iti is edema; proteinuria and hypoalbuminemia are not clinical but are biological features that allow to confirm the diagnosis in children. P6L19: relapse patients are usually named relapsers P6L19: the word refractory is not accurately employed. steroid dependent patients are often not refractory and the issue raised by steroid resistant patients is not those of steroid dependent. SRNS is dominated by the progression to ESRD in case of no response to calcineurin inhibitors while the main issue of SDNS along with all frequent relapsers is the duration of the disease and the exposure to immunosuppression. P6L25: most chiildren with these 2 phénotypes will progress to ESRD: it is not true; only SRNS patients with no response to immunosuppression will progress to ESRD. P6L29: genomic studies conducted....have suggested that most cases of refractory NS are likely due to genetic.... is not true at all in patients beyond the age of 1 year. P6L43: to write that "Previous studies have reported that humoral immunity has a close connection with PNS, especially systemic abnormalities of T-cell function, and previous studies provide evidence that minimal changes in PNS may be due to a circulating factor released by activated T cells" is confounding while T cells don't belong to humoral immunity. P6L50: Hodgkin disease is a B cell disease while the ReedSternberg cell is of B lineage P6L54: Recent studies have suggested that B cell differentiation dysfunction also affects the progression of PNS. reference 6 refers to autoimmune arthritis and reference 7 refers to lupus -nothing in relation to nephrotic syndrome. Study design: P8L3 to L17: patients with idiopathic nephrotic syndrome display microhematuria in 20 to 25% of the cases, increased blood pressure over the 90P in 21% of the cases, and abnormally increased serum creatinine in 15% of cases. It should be point out that all: patients with a response to prednisone or prednisolone within 4 weeks will be included except those with hypocomplementemia. Steroid resistant patients will be included if they either respond to calcineurin inhibitors or have a negative genetic testing, otherwise they belong to the frame of monogenic podocytopathies. patients with podocytopathies have to be clearly excluded from the study. 
VERSION 1 -AUTHOR RESPONSE
We would like to express our sincere thanks to the reviewers for their constructive and positive comments.
Responses to Reviewer 1
Response: None.
Responses to Reviewer 2 Response: We have added a description of the remaining patients with PNS, which has been mentioned in Page 4(line113-114).
3. Line 25: It is NOT true that the most with SDNS/SRNS will progress to ESRD within 5-10 years.
Children with SDNS rarely progress to ESRD and up to 70% of children with non-genetic forms of SRNS achieve remission after cyclosporine. The authors should correct their incorrect statement.
Response: Thank you for your suggestion. We have corrected the statement and added a description of the difficulty in treating steroid-resistant nephrotic syndrome (SRNS) and steroid-dependent nephrotic syndrome/frequent relapse nephrotic syndrome (SDNS/FRNS), which have been mentioned in Page 4(line120-124).
4. Because of the very different prognosis of children with SDNS vs. SRNS, I would recommend to handle these two groups separately and omit the term "refractory" NS which contains these two very different NS categories.
Response: A direct comparison between patients with FRNS/SDNS and patients with SRNS will not be performed in our protocol or study. The study focuses on the three different clinical phenotypes of patients with PNS, and the primary outcome is the analysis of the immunological genetic variants associated with the differences in immunological mechanisms between patients with steroid-sensitive nephrotic syndrome (SSNS) without FR and patients with SRNS or FRNS/SDNS.
Line 39:
The immunologic theory of the pathophysiology of PNS is very controversial. Therefore, the authors should suggest adding a sentence "However, the immunologic etiopathogenesis of NS still needs to be confirmed":
Response: The relevant sentence has been added to the revised manuscript, which have been mentioned in Page 4(line134-142).
6. Line 58: The authors should give the concrete numbers of the "annual incidence" of PNS in China (high) in comparison to other countries.
Response: Thank you for your constructive suggestion. A direct comparison of the annual incidence of PNS between China and other countries has not been reported. We have modified the statement in the revised manuscript, which have been mentioned in Page 5(line143-147). Response: Thank you for your kind reminder. We submitted the manuscript on December 20, 2018, and started the study on February 1, 2019. We received the editorial decision on May 16, 2019. Perhaps you reviewed the manuscript after February 1, 2019. According to the editorial policy, the status of our study is planning (before February 1, 2019) or ongoing (after February 1, 2019) . Therefore, the time at which the study began will not be changed.
9.Line 41: Consider changing the words "following conditions" by "inclusion criteria"
Response: The phrase "following conditions" has been replaced with "inclusion criteria", which has been mentioned in Page 6(line170).
10.Line 44: Change the term "high" by "nephrotic".
Response: The term "high" has been replaced with "nephrotic", which has been mentioned in Page 6(line172).
11.The correct international definition of nephrotic proteinururia is not ≥50 mg/kg but ≥40mg/kg/hour. The authors should give the protein/creatinine ration also in the SI unit: mg/mmol creatinine (should be ≥200 mg/mmol creatinine)
Response: According to the 2012 KDIGO guidelines, the definition of nephrotic proteinuria in the published literature is proteinuria >3.5 g per 24 hours (in children, >40 mg/m2/hr or PCR >2000 mg/g [>200 mg/mmol] or >300 mg/dL or 3+ on a urine dipstick) plus hypoalbuminemia and edema [1] . However, unlike adults, Chinese pediatricians tend to adopt proteinururia ≥50 mg/kg as the diagnostic criteria for childhood PNS in clinical practice to adjust for weight, an important confounding factor [2] [3] [4] . Additionally, we have described the protein/creatinine ratio in SI units (Page 6, line172-173).
[1] National Kidney Foundation． KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements， 2013， 3: 1-150. 
12.Line 60: The authors must explain what is the term "nephrotic-nephrotic" syndrome or delete it
Response: Thank you for your suggestion. "Nephrotic-nephrotic" syndrome means "nephritic type NS", a clinical phenotype of NS in Chinese guidelines for PNS [1] . We have deleted the term, which have been mentioned in . The readers will have a better understanding of our study. 
13.Page 8, line 12:
The correct definition of hypertension is BP "equal or greater" than the 95th pc.
Response: We have modified the definition of hypertension, which has been mentioned in Page 6(line188).
14.Page 9, line 10: The authors must precisely state in which clinical phenotype they will perform WES.
Response: The patients with SSNS without FR, SRNS, and FRNS/SDNS will be evaluated using whole exome sequencing (WES), which have been mentioned in Page 7(line220-221).
15.It is not appropriate to do WES in non-familial SSNS.
Response: To date, several lines of evidence indicate that the immune system plays a potentially crucial pathogenic role in non-genetic PNS [1] . To date, whole exome sequencing (WES) has been adopted in many cohort studies because of its lower cost, the lower amounts of DNA required, the possibility of comparatively more rapid turnaround, and greater sequencing depth [2] [3] [4] . In this prospective cohort study, we chose WES to evaluate the presence of genetic variants in immunerelated genes in patients with PNS divided into three subgroups (SSNS without FR, SRNS, and FRNS/SDNS). The SSNS without FR group will serve as the general control group. 16.The authors do not give any data on which immunological studies they are planning to performthey must append this.
Response: Thank you for your constructive suggestion. The study will evaluate the presence of genetic variants in immune-related genes in patients with PNS. These genes will be obtained from Kyoto Encyclopedia of Genes and Genomes Database (KEEG) immune system, which contains 21 immunological signaling pathways. These immunological genes potentially affect the progression of PNS, and an analysis of the KEGG pathways associated with the differentially expressed genes will be performed. A detailed description of the immunological signaling pathways is presented in Table 4 .
17.Treatment: The authors must state which initial steroid treatment schedule they will use (ISKDC?, APN?, other?)
Response: The initial steroid treatment schedule follows the Improving Global Outcomes Glomerulonephritis Work Group (KDIGO) guidelines, which have been mentioned in Page 8(line249-252).
18.The therapeutic schemes for immunosuppressant should include also oral cyclophosphamide.
Response: Schemes for oral cyclophosphamide therapy have been added, which has been mentioned in Page 8(line254).
19.The authors should give a scheme, which immunosuppressants will be used in which type of patients.
Response: The recommended immunosuppressants for patients with FRNS/SDNS and SRNS are shown in Table 5 .
20.Sample size calculation: 70-80% of PNS patients are SSNS (not 20-30%).
Response: In the original manuscript, the term SSNS was defined as sensitive to steroids without frequent relapse (SSNS without FR). We have corrected the definition in the revised manuscript, which has been mentioned in Page 10(line294-295).
21.Discussion: The first sentence "Childhood CKD is a multisymptomatic syndrome that occurs as a result of ..." is not correct and should be omitted.
Response: Thank you for your constructive suggestion. We have deleted the sentence.
22.Page 13, line 23: the children are NOT "progressing" to SSNS, but "becoming" -this should be corrected.
Response: We have replaced the term "progressing" with "becoming", which has been mentioned in Page 12(line365).
23. Figure 1: The subgroup of SSNS without SDNS/FRNS should be renamed from "SSNS" to "SSNS without FR"
Response: The subgroup of SSNS without SDNS/FRNS has been renamed in Figure 1 .
Responses to Reviewer 3
1.1-Title: Primary nephrotic syndrome means idiopathic nephrotic syndrome and membranous nephropathy while authors are clearly oriented to study the idiopathic nephrotic syndrome.
Response: Thank you for your suggestion. Idiopathic nephrotic syndrome (INS) is defined as NS of unknown origin. Primary nephrotic syndrome (PNS) is defined as NS originating from a primary glomerular defect. In published literatures, PNS is equivalent to INS [1] [2] [3] to distinguish it from secondary nephrotic syndrome and congenital nephrotic syndrome. Chinese scholars and doctors like use "PNS" on writing habits. The term "primary" has been replaced with "idiopathic" for clarity in the revised manuscript. 2.2-intro: P6L7: constellation of clinical signs: there is only one clinicla sign and iti is edema; proteinuria and hypoalbuminemia are not clinical but are biological features that allow to confirm the diagnosis in children.
Response: We have modified the sentence, which has been mentioned in Page 4(line109-110).
3.P6L19: relapse patients are usually named relapsers
Response: The term "relapse patients" has been replaced with "relapsers", which has been mentioned in Page 4(line116).
4.P6L19: the word refractory is not accurately employed. steroid dependent patients are often not refractory and the issue raised by steroid resistant patients is not those of steroid dependent. SRNS is dominated by the progression to ESRD in case of no response to calcineurin inhibitors while the main issue of SDNS along with all frequent relapsers is the duration of the disease and the exposure to immunosuppression.
Response: Thank you for your insightful suggestion. Although different mechanisms and prognoses have been reported between patients with steroid-dependent nephrotic syndrome (SRNS) and steroid-resistant nephrotic syndrome (SRNS), refractory nephrotic syndrome is recognized as a steroid-dependent (SDNS), steroid-resistant (SRNS) or frequently relapsing nephrotic syndrome (FRNS) [1] [2] [3] . Suitable therapies for FRNS/SDNS and SRNS represent a challenge and remain to be explored [4] . 
